Shares of PetIQ (NASDAQ:PETQ) have been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $27.40.
A number of equities research analysts have commented on the company. BidaskClub upgraded PetIQ from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded PetIQ from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Friday, March 16th. Finally, Jefferies Group reiterated a “buy” rating and issued a $27.00 price target on shares of PetIQ in a research report on Monday, January 8th.
In other PetIQ news, CEO Mccord Christensen sold 40,000 shares of the company’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $24.92, for a total value of $996,800.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO John Newland sold 5,500 shares of the company’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $24.83, for a total value of $136,565.00. The disclosure for this sale can be found here.
NASDAQ PETQ opened at $26.60 on Wednesday. PetIQ has a 12 month low of $17.03 and a 12 month high of $28.23. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.99 and a quick ratio of 3.56.
PetIQ, Inc is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield.
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.